Can chemoprevention reduce the risk of progression to malignancy?
The full article is accessible to AMA members and paid subscribers. If you are an AMA member or have a subscription login to read more or purchase a subscription now.
1 Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, VIC.
2 Department of Gastroenterology, Box Hill Hospital, Box Hill, VIC.
Correspondence:
Competing interests:
G S H has acted as a consultant to AstraZeneca, Novartis and Pharmacia (Pfizer), and has received research support, sponsored travel and honoraria for speaking from AstraZeneca, Novartis and Wyeth. S N has acted in an advisory capacity to Pharmacia and has received research support, sponsored travel and honoraria for speaking from AstraZeneca and Pharmacia (Pfizer).
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.
G S H has acted as a consultant to AstraZeneca, Novartis and Pharmacia (Pfizer), and has received research support, sponsored travel and honoraria for speaking from AstraZeneca, Novartis and Wyeth. S N has acted in an advisory capacity to Pharmacia and has received research support, sponsored travel and honoraria for speaking from AstraZeneca and Pharmacia (Pfizer).